

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Treatments for non-small-cell lung cancer [ID6234]

#### Final stakeholder List

Consultees	Commentators
<p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• ALK Positive UK</li> <li>• Asthma and Lung UK</li> <li>• Black Health Agency for Equality</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• EGFR Positive UK</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Macmillan Cancer Support</li> <li>• Maggie’s Centres</li> <li>• Marie Curie</li> <li>• Oncogene-Driven Lung Cancer Patient Alliance UK</li> <li>• Roy Castle Lung Cancer Foundation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tenovus Cancer Care</li> <li>• UK Lung Cancer Coalition</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Anaesthetists</li> <li>• Association of Cancer Physicians</li> <li>• Association of Respiratory Nurse Specialists</li> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Geriatrics Society</li> <li>• British Institute of Radiology</li> <li>• British Oncology Pharmacy Association</li> <li>• British Psychosocial Oncology Society</li> <li>• British Society of Interventional Radiology</li> <li>• British Thoracic Oncology Group</li> <li>• British Thoracic Society</li> <li>• British Transplantation Society</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> <li>• Amgen (sotorasib)</li> <li>• Aspire Pharma (pemetrexed)</li> <li>• Bayer (laroctrectinib)</li> <li>• Boehringer Ingelheim (nintedanib)</li> <li>• Bristol Myers Squibb (nivolumab, paclitaxel)</li> <li>• Celltrion Healthcare UK (bevacizumab)</li> <li>• Dr Reddy’s Laboratories (pemetrexed)</li> <li>• Eli Lilly (selpercatinib, pemetrexed)</li> <li>• Genus Pharmaceuticals (pemetrexed)</li> <li>• Hospira UK (cisplatin, carboplatin, oxaliplatin, docetaxel, paclitaxel, gemcitabine, vinorelbine, pemetrexed)</li> <li>• Inceptua (paclitaxel)</li> <li>• Medac (oxaliplatin, vinorelbine)</li> <li>• Merck Sharp &amp; Dohme UK (pembrolizumab)</li> </ul>

Stakeholder list for the evaluation of treatments for non-small-cell lung cancer [ID6234]

Issue date: August 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.

Page 1 of 3

Consultees	Commentators
<ul style="list-style-type: none"> <li>• Cancer Research UK</li> <li>• Lung Cancer and Mesothelioma Clinical Expert Group</li> <li>• Lung Cancer Nursing UK</li> <li>• National Heart and Lung Institute</li> <li>• NHS Blood and Transplant</li> <li>• Primary Care Respiratory Society</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Mylan (pemetrexed)</li> <li>• Organon Pharma (bevacizumab)</li> <li>• Pfizer (pemetrexed, bevacizumab)</li> <li>• Pierre Fabre (vinorelbine)</li> <li>• Roche (atezolizumab, bevacizumab entrectinib)</li> <li>• Sandoz (cisplatin, pemetrexed)</li> <li>• Seacross Pharmaceuticals (oxaliplatin, docetaxel, paclitaxel)</li> <li>• Takeda (mobocertinib)</li> <li>• Thornton and Ross (bevacizumab)</li> <li>• Zentiva (bevacizumab)</li> </ul> <p><u>Pathway companies</u></p> <ul style="list-style-type: none"> <li>• AmaroX (erlotinib)</li> <li>• AstraZeneca (durvalumab, osimertinib)</li> <li>• Boehringer Ingelheim (afatinib)</li> <li>• Cipla EU (gefitinib)</li> <li>• Merck (tepotinib)</li> <li>• Novartis (ceritinib, dabrafenib, trametinib)</li> <li>• Pfizer (crizotinib, dacomitinib, lorlatinib)</li> <li>• Roche (alectinib)</li> <li>• Takeda (brigatinib)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Lung Cancer Group</li> <li>• Cochrane UK</li> <li>• Genomics England</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations

from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

## **Definitions:**

### Consultees

Organisations that accept an invitation to participate in the development of the model (please see non-small cell lung cancer process statement); national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

All non-company consultees that engage in the evaluation process may be asked to submit evidence or statements and are invited to respond to consultations.

### Commentators

Organisations that engage in the evaluation process and may be asked to submit evidence or statements, are able to respond to consultations. These organisations are: companies that market comparator technologies; pathway companies (see below) Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

### Pathway company

A pathway company is a company which has a technology for NSCLC that meets the eligibility criteria for technology appraisal guidance or is expected to get regulatory approval beyond 24 months. They are organisations that engage in the development of pathway.